ANArun Prabhakaran Nair

Arun Prabhakaran Nair

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arun Prabhakaran Nair has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disseminated tuberculosis masquerading as Tolosa-Hunt syndrome in initial presentation: A case report with literature review

    by Sreethish Sasi, Arun Prabhakaran Nair, Jouhar Kolleri, Aseel Alzibdeh, Muna S. Rahman Al Maslamani


  • Open Access

    Efficacy of Anakinra in the Management of Patients with COVID-19 Infection: A Randomized Clinical Trial

    by Eman Zeyad I. Elmekaty, Aya Maklad, Rawan Abouelhassan, Waqar Munir, Mohamed Izham Mohamed Ibrahim, Arun Nair, Rim Alibrahim, Fatima Iqbal, Ahmad Al Bishawi, Alaaeldin Abdelmajid, et al.

    Background The global pandemic of COVID-19 infections continues to grow worldwide, with rising number of deaths day by day. The hyperinflammation state contributes to the multiorgan failure associated with COVID-19 infections. This study aims to explore the efficacy and safety of anakinra in COVID-19 patients with both respiratory distress and cytokine release syndromes. Methods This was an open-label, multicenter, randomized clinical trial. Patients were randomized in 1:1 ratio to receive standard of care (SOC) alone, or anakinra plus SOC. Adults with confirmed COVID-19 infection with evidence of both respiratory distress and cytokine release syndrome were included. The primary outcome was treatment success at day 14, defined as WHO clinical progression score of ≤3. The primary analysis was based on intention-to-treat population, with p-value of Results A total of 80 patients were enrolled in the study. The mean age was 49.9 years (SD=11.7), with 82.5% (n=66) male patients. The primary outcome was not statistically different (87.5% (n=35) in anakinra group vs. 92.5% (n=37) in SOC group, p=0.712). The majority of reported adverse events were mild in severity and not related to the study treatment. Increased aspartate aminotransferase was the only significant adverse event (35% (n=14) in anakinra group vs. 15% (n=6) in SOC group, p=0.039); yet, was not associated with treatment discontinuation. Conclusion In patients with severe COVID-19 infection, the addition of anakinra to SOC treatment was not associated with significant improvement in the WHO clinical progression scale. Further studies investigating patients’ subgroups that might benefit from anakinra are warranted. The trial was registered at ClinicalTrials.gov (NCT04643678).


  • Open Access

    Coronavirus Disease-19-associated Acute Pancreatitis: Report of Three Cases and Review of Case Reports

    by Fahmi Yousef Khan, Theeb Osama Sulaiman, Arun Prabhakaran Nair, Mohamed Elmudathir Osman

    BACKGROUND: Reports on coronavirus disease 2019 (COVID-19) associated with acute pancreatitis continue to emerge. In this series, we present three cases of acute pancreatitis associated with COVID-19 with no obvious etiology. CASE REPORTS: The first case was a 47-year-old man who presented with severe abdominal periumbilical pain, preceded by fever and dry cough. Based on a positive COVID-19 polymerase chain reaction (PCR) test and elevated serum amylase and lipase >3 times the upper normal limit, the diagnosis of COVID-19 and acute pancreatitis were established. The next case was a 57-year-old man with confirmed COVID-19 who developed severe epigastric pain radiating to the back and was associated with nausea and vomiting. His serum amylase and lipase were elevated >3 times the upper normal limit confirming the diagnosis of acute pancreatitis. The third case was a 31-year-old man who presented to the emergency department with a few hours of severe epigastric pain radiating to the back associated with nausea and vomiting. Two days before his presentation, he had a runny nose and fever. A combination of serum amylase and lipase elevation, >3 times the upper normal limits, and a positive COVID-19 PCR test were obtained concurrently, confirming the diagnosis of COVID-19 associated acute pancreatitis. All patients were admitted to the Mesaieed Hospital COVID-19 facility and received treatment for COVID-19 according to our local guidelines, while acute pancreatitis was treated conservatively. All three patients were discharged in good condition. CONCLUSION: This case series suggests a possible correlation between COVID-19 and acute pancreatitis.


  • Open Access

    Epidemiological characteristics of de novo hepatitis B infection in liver transplant recipients—An experience from a tertiary care centre in Qatar

    by Arun Prabhakaran Nair, Sreethish Sasi, Muna S. Al‐Maslamani, Prem Chandra, Samar A. Hashim, Sulieman Abu Jarir, Moutaz Derbala

    Background: The emergence of hepatitis B surface antigen in a patient with previously negative hepatitis B virus (HBV) serology post‐orthotropic liver transplant (OTLX) is known as de novo hepatitis B (DNHB). As there are no data on patients with DNHB available from Qatar, we aim to do a pioneer study indexing their clinical profile and epidemiology of patients with DNHB in Qatar.Materials and Methods: This descriptive epidemiological study was done by retrospectively reviewing records of 159 post‐OTLX patients. HBV serology of these patients post‐OTLX was reviewed, and 17 were identified as DNHB cases. Baseline epidemiological characteristics were defined and compared between DNHB cases and the rest. DNHB cases were analyzed statistically using the chi‐square test and Kaplan‐Meier curve.Results: The majority of the subjects were men (65%) and Qataris (40%). Mean age was 57.4 ± 12.5 years. Bulk of them underwent OTLX in China (44%). The overall incidence of DNHB was 10.7%, with transplants in China having significantly higher incidence than transplants from all other countries. The mortality rate was 23.5% in DNHB cases compared to 2.8% in non‐DNHB. 67% of patients survived at least 64 months after the diagnosis of DNHB. Five‐year survival did not vary significantly between those with DNHB and those without.Conclusion: Orthotropic liver transplant in centers selecting donors liberally without screening for HBV poses the risk of DNHB. We recommend having protective levels of HBs antibodies before OTLX. Prophylactic antiviral treatment should be considered until peri‐operative HBV transmission has been excluded by screening hepatic tissue for HBV DNA.